Trial reportGut2017
A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia.
Trial report in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 4 syntheses or guidelines pooled it, 250 citations in OpenAlex.
- AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.Gastroenterology · 2024Guideline
- Guideline
- Pooled it
- Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.Updates in surgery · 2019Guideline
- Closure strategies post-EMR for esophageal SMTs.Surgical endoscopy · 2026Article
- Ligation-assisted endoscopic mucosal resection versus endoscopic submucosal dissection for small gastrointestinal deep-layer lesions: A retrospective cohort study.The Journal of international medical research · 2026Article
- Mucosal Versus Submucosal Lymphovascular Invasion in Early Esophageal Cancer.Annals of surgical oncology · 2026Article
- Endoscopic Therapy in Barrett's Esophagus.Visceral medicine · 2026Article
- Hydrogel adhesives for upper gastrointestinal wound healing.Theranostics · 2026Review
- Review
- Comparison of Primary Endoscopic Submucosal Dissection versus Primary Endoscopic Mucosal Resection for Barrett's Esophageal Neoplasia Treatment.Endoscopy international open · 2026Article
- Esophageal ESD Training; Perspective of West vs. East.Current gastroenterology reports · 2025Review
- Cancer Burden on Piecemeal Endoscopic Resection of Early Adenocarcinoma in Barrett's Oesophagus Correlates With the Risk of Neoplastic Recurrence.United European gastroenterology journal · 2025Article
- Risk stratification for stricture formation after endoscopic submucosal dissection for esophageal dysplasia.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Carcinoma of Esophagus.Journal of gastroenterology and hepatology · 2025Review
- Review
- Non-Curative Endoscopic Submucosal Dissection: Current Concepts, Pitfalls and Future Perspectives.Journal of clinical medicine · 2025Review
- Current status and perspectives of esophageal cancer: a comprehensive review.Cancer communications (London, England) · 2025Review
- Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett's esophagus-related neoplasia.Endoscopy international open · 2025Article
- Expert assessment of infiltration depth and recommendation of endoscopic resection technique in early Barrett cancer.United European gastroenterology journal · 2024Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor endoscopic resection of early GI neoplasia, endoscopic submucosal dissection (ESD) achieves higher rates of complete resection (R0) than endoscopic mucosal resection (EMR). However, ESD is technically more difficult and evidence from randomised trial is missing.
objectiveWe compared the efficacy and safety of ESD and EMR in patients with neoplastic Barrett's oesophagus (BO).
designBO patients with a focal lesion of high-grade intraepithelial neoplasia (HGIN) or early adenocarcinoma (EAC) ≤3 cm were randomised to either ESD or EMR. Primary outcome was R0 resection; secondary outcomes were complete remission from neoplasia, recurrences and adverse events (AEs).
resultsThere were no significant differences in patient and lesion characteristics between the groups randomised to ESD (n=20) or EMR (n=20). Histology of the resected specimen showed HGIN or EAC in all but six cases. Although R0 resection defined as margins free of HGIN/EAC was achieved more frequently with ESD (10/17 vs 2/17, p=0.01), there was no difference in complete remission from neoplasia at 3 months (ESD 15/16 vs EMR 16/17, p=1.0). During a mean follow-up period of 23.1±6.4 months, recurrent EAC was observed in one case in the ESD group. Elective surgery was performed in four and three cases after ESD and EMR, respectively (p=1.0). Two severe AEs were recorded for ESD and none for EMR (p=0.49).
conclusionsIn terms of need for surgery, neoplasia remission and recurrence, ESD and EMR are both highly effective for endoscopic resection of early BO neoplasia. ESD achieves a higher R0 resection rate, but for most BO patients this bears little clinical relevance. ESD is, however, more time consuming and may cause severe AE. TRIAL REGISTRATION NUMBER: NCT1871636.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.